Only after treatment with BTZ for 48 h, was there a significant decrease in MGMT levels, consistent with its stability and relatively long half-life of ~60 h in promoter unmethylated cancer cells.41 Thus, BTZ+TMZ 50 μM combination treatment for 48 h (in vitro sensitisation dose determined to be a quarter of the IC50 200 μM TMZ dose) precisely induced O6-MeG adducts that could not be repaired, as BTZ had effectively attenuated MGMT protein at this time point. The gene discussed is MGMT; the disease is cancer.